Aegerion Pharmaceuticals, Inc. (AEGR) SEC Filing 8-K Material Event for the period ending Friday, November 25, 2016

Aegerion Pharmaceuticals, Inc.

CIK: 1338042 Ticker: AEGR

View differences made from one to another to evaluate Aegerion Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aegerion Pharmaceuticals, Inc..


Assess how Aegerion Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aegerion Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2016 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
Ticker: AEGR
CIK: 1338042
Form Type: 8-K Corporate News
Accession Number: 0001104659-16-159620
Submitted to the SEC: Tue Nov 29 2016 5:07:19 PM EST
Accepted by the SEC: Tue Nov 29 2016
Period: Friday, November 25, 2016
Industry: Pharmaceutical Preparations
  1. Bylaw Change
  2. Change in Assets
  3. Change in Control
  4. Ending Agreement
  5. Event for Officers
  6. Financial Exhibit
  7. Listing Status
  8. New Agreement
  9. Security Holders Change

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: